Biogen expecting gradual Spinraza uptake

In its 4Q16 and full-year 2016 earnings presentation Thursday, Biogen Inc. (NASDAQ:BIIB) management said it expects gradual uptake of spinal muscular atrophy (SMA) drug Spinraza nusinersen in 2017 as the company navigates payer relationships and

Read the full 358 word article

User Sign In